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Purpose of review—This review discusses the utility of pathogen-specific antibody biomarkers 
for improving estimates of the population burden of waterborne infections, assessing the fraction 
of infections that can be prevented by specific water treatments, and understanding transmission 
routes and the natural history and ecology of disease in different populations (including 
asymptomatic infection rates).
Recent findings—We review recent literature on the application of pathogen-specific antibody 
response data to estimate incidence and prevalence of acute infections and their utility to assess the 
contributions of waterborne transmission pathways. Advantages and technical challenges 
associated with the use of serum versus minimally invasive salivary antibody biomarkers in cross-
sectional and prospective surveys are discussed.
Summary—We highlight recent advances and challenges and outline future directions for 
research, development, and application of antibody-based and other immunological biomarkers of 
waterborne infections.
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Introduction
Waterborne infections cause an estimated two million deaths and four billion episodes of 
diarrheal illness per year worldwide [1]. Waterborne diseases will continue to be of broad 
public health importance as peri-urban populations rapidly expand at a pace that exceeds 
developing countries’ abilities to invest in infrastructure [2]. While most of these illnesses 
occur in developing countries, industrialized countries also bear a substantial burden of 
waterborne diseases [3]. For high-income countries, if investments in water supply and 
sewer systems do not enable proper maintenance and timely replacement of aging 
infrastructure, the risk of waterborne infections is likely to increase [4].
Waterborne disease outbreaks are defined as two or more persons experiencing a similar 
illness after exposure to water where epidemiologic evidence implicates water as the 
probable source of the outbreak [5]. Waterborne pathogens that result in human infections 
include bacteria (e.g., Campylobacter spp., Shigella spp.), viruses (e.g., norovirus, rotavirus), 
and protozoa (e.g., Cryptosporidium spp., Giardia spp.), and these pathogens may be 
conveyed to humans via drinking and/or recreational water transmission routes [6]. The 
health outcome most commonly associated with exposure to waterborne pathogens is acute 
gastrointestinal illness (AGI). AGI is defined in various ways, and definitions used in 
epidemiological research range widely [7]. One commonly used definition is as follows: 
diarrhea (three or more loose stools in a 24-h period), vomiting, nausea, stomach ache, fever, 
and/or interference with regular activities (missed time from work or school or missed 
regular activities as a result of illness) [8–10]. Other illnesses caused by waterborne 
pathogens include viral hepatitis (hepatitis A and E viruses [11]), skin and soft tissue 
infections and sepsis (Vibrio spp., Staphylococcus aureus [12]), primary amoebic 
meningoencephalitis (Naegleria fowleri [13]), and pneumonia (Legionella pneumophila 
[14]).
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In this review, we summarize the latest evidence on use of pathogen-specific antibodies as 
biomarkers (defined as “any substance, structure, or process that can be measured in the 
body or its products and can influence or predict the incidence of outcome or disease” [15]) 
of infection for the waterborne pathogens that cause the greatest population burden of AGI 
in the USA (norovirus, Shiga toxin-producing E. coli, and Cryptosporidium spp.) [16] and in 
developing countries globally (rotavirus, Cryptosporidium spp., Shigella, Giardia spp., 
Vibrio cholerae, and Campylobacter spp.) [17, 18]. We also include hepatitis A and E 
viruses because these pathogens are the most common causes of feces-transmitted acute 
viral hepatitis worldwide (Table 1) [19, 20]. Such pathogen-specific antibody biomarkers 
represent promising tools to identify causative agents in population-based studies of AGI, 
including waterborne disease outbreak investigations, surveillance studies, and observational 
and randomized intervention studies to test hypotheses related to transmission routes, water 
treatments, and disease ecology. Because not all individuals who become infected with 
waterborne pathogens will experience symptoms of AGI—i.e., a waterborne infection may 
be asymptomatic (without clinical disease) or symptomatic (clinical disease observable) [21]
—biomarkers of host immunological response can be used to identify a causative pathogenic 
agent and estimate symptomatic and/or asymptomatic waterborne disease burden. 
Knowledge of the waterborne pathogens responsible for asymptomatic infections can 
improve estimates of waterborne infections in source populations and advance 
understanding of upstream risk factors and transmission routes. Not knowing these can 
hinder the development of effective prevention strategies to reduce waterborne outbreaks 
and/or contamination events (e.g., via infrastructure improvements or other interventions 
prior to onset of symptoms).
We review the challenges in measuring population burdens of infection that can be attributed 
to waterborne versus other transmission routes (contaminated food, hygiene, sanitation, 
person-to-person and animal-to-person contact). Antibodies as biomarkers of waterborne 
infections are then discussed to highlight their current and future utility in population-based 
settings. Antibody responses to specific pathogens are described as they relate to measuring 
immunoconversions (defined as a change from antibody negative to antibody positive in 
serial samples or a four-fold increase in antibody titer in serial samples), rates, and time 
intervals of infection. The use of antibody biomarkers in serum is presented, followed by the 
discussion of novel salivary antibody biomarkers and their potential to improve upon 
estimates of waterborne infections. The utility of antibody biomarkers for detection of acute 
and chronic infections in population-based settings is discussed, including how estimates of 
the incidence of acute short-term infections can be obtained within the context of both cross-
sectional and prospective study designs. Finally, the technical challenges involved with using 
minimally invasive saliva samples as a matrix for the detection of pathogen-specific 
antibodies are presented along with future directions for salivary immunoassay work.
Challenges with Epidemiologic Estimates of Waterborne AGI in Population-Based Settings
The outcome most commonly employed in epidemiologic studies of waterborne disease is 
self-reported AGI symptoms. Because most AGI symptoms are self-limited, only a small 
proportion of the individuals who experience AGI actually seek medical care and have a 
stool sample submitted for testing. Furthermore, clinical diagnostic laboratories are not 
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always able to identify a pathogenic agent responsible for AGI symptoms [22]. Thus, only a 
small proportion of AGI disease will be captured by studies of, or reporting systems 
involving, patient populations seeking a clinical diagnosis (Fig. 1). AGI symptoms are also 
non-specific, with numerous pathogens and transmission routes that must be investigated in 
order to determine the etiologic agent. These features of AGI symptoms mean that 
epidemiologic studies that rely upon AGI as a primary outcome may not provide an accurate 
estimate of the population burden of disease. The ability to determine a host's immunologic 
response to specific pathogens that are responsible for waterborne infections could improve 
the specificity and decrease the misclassification of AGI in epidemiologic studies. 
Biomarkers of pathogen-specific host immunologic response could improve studies of the 
effects of improved water treatment and/or source water protection as well as advance 
understanding of pathogen exposure (e.g., spatial and temporal distribution) and modifiable 
factors that are associated with progression from asymptomatic to symptomatic states of 
infection (e.g., natural history and ecology of disease) in populations. For example, objective 
biomarkers of asymptomatic waterborne infections have helped identify low water pressure 
at the faucet as an important risk factor for self-reported diarrhea in the control group of a 
case-control study of sporadic cryptosporidiosis [23].
Most evidence of waterborne transmission in developed countries comes from outbreaks of 
infectious diseases. In the USA, the Centers for Disease Control and Prevention (CDC) as 
well as state and local authorities investigate outbreaks and attempt to identify the source. 
CDC publishes the biannual Morbidity and Mortality Weekly Report on outbreaks 
associated with drinking and recreational water sources. For example, in 2011–2012 for 
drinking water, a total of 32 outbreaks were reported and associated with 431 illnesses, 102 
hospitalizations, and 14 deaths [16]. For recreational water in 2011–2012, there were 90 
outbreaks that resulted in at least 1788 cases, 95 hospitalizations, and one death [24].
Knowledge of the pathogen-specific etiology of waterborne infections would help identify 
different risk factors and transmission routes, which can improve the evidence base for 
decision making about management and prevention strategies. A classic example of this is 
the massive waterborne outbreak of cryptosporidiosis in Milwaukee in 1993 when the 
chlorine-based disinfectant used had little effect on Cryptosporidium parvum oocysts and 
the drinking water treatment plants consequently had to investigate alternative disinfectants 
such as UV light [25]. Another example is a study of the presence of enteric viruses in non-
disinfected drinking water from municipal wells and their relation with community 
incidence of AGI [26]. In this study, the authors noted a positive association between 
norovirus genogroup I (GI) and AGI. But, the associations between the presence of other 
enteric viruses—adenovirus and echovirus serotypes—and AGI were not statistically 
significant. This lack of association could be due to misclassification and/or the non-
specificity of AGI as an outcome in epidemiologic studies (e.g., potential influence of 
measurement error due to participant self-reporting of AGI symptoms).
Waterborne outbreaks usually occur from causative factors such as weather events, wastes 
from animals, agriculture, or humans, and failures in water treatment [27]. Drinking water-
associated outbreaks are often caused by contaminated source waters, inadequacies in 
treatment, or contamination occurring within the distribution system [28]. Whereas, 
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recreational water-associated outbreaks have been attributed to swimming in waters 
impacted by inadequate chlorination or other disinfection (swimming pools) [29], fecal 
contamination shed by swimmers (swimming pools and natural waters) [30], runoff from 
publicly owned treatment work (POTW) wastewater effluents, sanitary and combined sewer 
overflows of untreated sewage, private on-site septic systems, agricultural production, and 
wildlife [31].
Most cases of waterborne infections are sporadic or diffuse, low-level outbreaks. Ingestion 
of waterborne pathogens can also result in a completely asymptomatic infection depending 
on the interplay of pathogen-specific and host-specific factors, such as a pathogen's 
virulence and a host's immune response [32]. They may be caused by deficiencies in 
drinking water treatment, resulting in contamination with waterborne pathogens, and 
transmission to consumers [33]. Waterborne pathogens that are resistant to chlorination 
(especially Cryptosporidium spp.) [34] or physical removal (especially viruses) can pass 
through the water treatment barrier and contaminate tap water even when water quality 
indicators based on surrogate bacteria (total and/or fecal coliforms, E. coli) are within the 
regulatory limits [35]. Viruses, such as noroviruses, can filter through the soil, contaminate 
shallow groundwater sources and present a health risk in drinking water systems that are 
groundwater supplied and do not use chemical disinfection [26]. Individual sporadic cases of 
AGI usually cannot be linked to a specific source in the framework of routine surveillance, 
contributing to the underestimation of waterborne infections in the population.
Antibody Biomarkers of Waterborne Infection
Specific antibody responses can be used as biomarkers of infection in epidemiological 
studies to estimate the prevalence and incidence of infections and to assess the contribution 
of waterborne transmission. Different pathogens result in different temporal distributions of 
antibody response and infection. Both symptomatic and asymptomatic infections typically 
cause an antibody response in the host [33]. A preexisting antibody response can be a factor 
affecting host's susceptibility to re-infection or the probability of developing symptoms if 
infection occurs [36]. The presence of antibodies specific to the pathogen of interest in 
biological samples (e.g., serum, saliva, stool, breast milk) is an indication of current or prior 
infection [33]. The major immunoglobulin isotypes (IgG, IgA, IgM) have different utility as 
estimates of population disease frequency and burden. Single time-point measurements of 
pathogen-specific IgG have utility as an estimate of historical/prior exposure or prevalent 
infection, whereas IgA and/or IgM has utility as an estimate of acute phase or incident 
infection [37, 38]. Immunoconversion is used to detect incident infections in prospective 
survey settings. This change from an antibody-negative sample to an antibody-positive 
sample in a time series of two or more samples, or a fourfold increase in antibody titer in a 
time series of two or more antibody-positive samples, is used to measure new, acute cases in 
a defined population over a defined time period [39–41].
Serologic Antibody Response
Serum is the most accurate and widely used matrix to monitor population immune responses 
to pathogens. Sera can be collected by sampling populations, or residual blood banks can be 
used. However, there are significant drawbacks to both since blood collection requires 
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trained individuals to visit participants [42] and may be cost prohibitive along with low 
response rates that have been shown in Europe due to the invasive nature of blood collection 
[43, 44]. Its application in prospective studies and especially in studies involving children is 
problematic due to high attrition and low compliance [45]. Relying on previously collected 
samples from sera banks overcomes these issues; however, they are usually anonymous with 
limited data available on the patient and, importantly, their background as it pertains to 
water, sanitation, and hygiene-related behaviors and activities [46]. However, a number of 
studies have successfully used seroepidemiological methods in the context of waterborne 
disease [47, 48]. Frost et al. found that people who live in cities using surface-derived 
drinking waters had an increased risk of Cryptosporidium infection compared to those using 
drinking water from municipal groundwater sources [47]. And, in the context where 
sanitation conditions are poor and clean water supplies are limited, Priest et al. found IgG 
antibody responses during Cryptosporidium infections with C. parvum, Cryptosporidium 
felis, and Cryptosporidium meleagridis and with four different subtypes of Cryptosporidium 
hominis [48].
Salivary Antibody Response
The utility of novel salivary antibody biomarkers as a measure of host immune response to 
specific pathogens has the potential to improve upon estimates of waterborne infections that 
rely on invasive collection of serum. Saliva collection is minimally invasive and can be self-
collected and returned by mail [49••], allowing for a larger sampling of the population than 
is possible with serum. Saliva is a mixture of secretions from salivary glands. Oral fluid 
contains saliva (enriched with secre-tory IgA) and crevicular fluid (flows from between the 
gum margins and teeth) and is enriched with serum antibodies [50]. Some oral fluid 
sampling techniques are specifically designed to collect samples enriched with crevicular 
fluid for measurements of systemic antibody responses [51, 52, 53•].
Salivary assays have been used to identify various viral, bacterial, and parasitic infections 
[54] (see Table 2). Measuring antibodies in saliva is appropriate for both children and adults 
and is suitable for population-based surveillance settings [40]. Salivary immunoassays have 
been developed for pathogens such as Helicobacter pylori, Toxoplasma gondii, 
Cryptosporidium, and noroviruses [52••]. Griffin et al. (2011) applied the Luminex xMAP 
microsphere-based technology (Luminex Corp., Austin, TX) assay to measure antibodies to 
multiple pathogens within a single saliva sample volume [52••]. The Norwalk virus assay 
developed in Griffin et al. (2011) was subsequently validated using samples from a human 
volunteer challenge study [53•]. A similar salivary immunoassay is being applied to measure 
the incidence of norovirus infections following recreational water exposures at beaches in 
Puerto Rico, Iowa, and Wisconsin where saliva has been collected as part of the 
Environmental Protection Agency's National Epidemiologic and Environmental Assessment 
of Recreational Water Study [55].
An important challenge in using saliva to measure immunologic responses is the greater 
inter- and intra-individual variability in saliva composition and immunoglobulin levels. 
While saliva contains a high level of secretory IgA (SIgA) antibodies, there can be 
significant diurnal, age, and oral health-related variability [56], making these factors 
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important to consider in community-based field studies. The salivary concentrations of IgG 
and IgM isotypes are lower than in serum. Thus, a salivary antibody assay targeting IgG has 
to be sensitive enough to quantify low-intensity antibody responses. Typically, it is necessary 
to assay saliva at relatively low dilutions, where matrix effects (e.g., inhibition, high 
background signal) can be pronounced in some pathogen-specific antibody assays [57]. For 
each pathogen-specific antibody target, it is critical to optimize the conditions that may 
influence assay performance and sensitivity and specificity [53•].
There is scant evidence on the temporal patterns of salivary antibody responses to infection 
with a specific pathogen (peak levels and rates of decline for different antibody isotypes). 
Our current understanding of generalized trajectories (Fig. 2) comes from prospective 
studies using serum or saliva from individuals with confirmed infections, such as volunteer 
challenge studies for norovirus [40, 58, 59], Cryptosporidium [60], Giardia lamblia [61, 62], 
and Shigella [63]. The pattern of antibody isotypes may be used in diagnostic and research 
settings to provide information on the infection state (acute versus convalescent) and to 
assess the timing of infection [33]. Typically, the IgA and/or IgM response to a waterborne 
pathogen ramps up before the IgG response [36, 58, 59]. The generalized trajectories of 
different antibody isotype levels during a transient acute infection from a waterborne 
pathogen are depicted in Fig. 2. After the convalescent stage, IgG pathogen-specific 
antibodies may remain detectable for weeks to years, depending on the causative agent, and 
may remain elevated above preinfection levels [36, 64]. There can be vast differences in 
these temporal patterns of antibody responses depending on the pathogen causing the 
infection. Thus, an area of future work is to develop population-based antibody infection 
curves for specific waterborne pathogens.
Platforms and Assay Types
Various immunoassay platforms have different costs, quantitation levels, dynamic ranges, 
and multiplexing potentials [65]. The most basic of these platforms is the indirect enzyme 
immunoassay; however, the low through-put and high sample volume requirements make it 
less desirable for population-based analyses where multiple pathogens are being analyzed 
and sample volume is limited. Multiplex immunoassays, such as those based on the Luminex 
(Luminex Corp., Austin, TX) microbead suspension fluorescence immunoassay platform, 
require a low sample volume to analyze multiple pathogen-specific antibody analytes 
simultaneously. They are also less labor intensive because more data are generated per test/
analyte and thus are more cost-effective [52••, 53•, 66–69]. Another immunoassay platform 
that is used and allows multiplexing is the Meso Scale Discovery (MSD; Rockville, M D) 
electrochemiluminescence (ECL) platform. Platforms that facilitate multiplexing can be 
used to expand the range of available options for testing the signal of pathogen-specific 
antibody responses as well as background signals. The adjustment of the pathogen-specific 
antibody signal for background signals, such as those produced by total IgA or total IgG or 
by antigen tags such as glutathione-S-transferase (used during antigen purification), can 
improve the performance of antibody assays [52••, 53•]. Multiplexing of these target signals 
can also reduce excess use of biospecimen sample volume because all signals can be 
measured in one sample volume in a single reaction well. Thus, multiplexing testing 
platforms can facilitate a broader application of antibody testing of serum and/or saliva 
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biospecimens in population-based epidemiologic investigations of diverse waterborne 
pathogens.
Applications of Pathogen-Specific Antibody Biomarkers in Population-Based Studies of 
Waterborne Infections
To improve current epidemiologic estimates of AGI from waterborne pathogens in 
population-based settings, pathogen-specific antibody biomarkers can be used. For chronic 
infections, antibody responses can be positive or negative and can be validated against 
diagnostic tests. The proportion of IgG-positive results in serum or saliva can serve as a 
direct measure of infection prevalence in the population [70, 71]. In contrast, for acute short-
term infections, such as noroviruses and Cryptosporidium, the presence of pathogen-specific 
antibodies in serum or saliva may indicate an ongoing infection or more commonly a past 
infection with or without symptoms. Thus, the concept of “positive” antibody response to an 
acute short-term infection or seroprevalence of positive responses often reflects the 
proportion of results above an arbitrary threshold, such as a detection limit of the method or 
by standardizing response intensities to the response of a reference sample of positive 
control sera [72–75] or saliva.
One approach to estimating incidence of acute infections using antibody data is to use 
immunoconversion in prospective study settings as a marker of new infections. The 
sensitivity and specificity of an immunoconversion test are related to its ability to detect 
infections that occur during the interval between two sampling dates. In prospective studies, 
biological sampling (serum or saliva) can be combined with symptom diaries to produce 
information on the association of certain infections with specific types of symptoms and/or 
the association of exposures with infections or interventions (designed to reduce exposure) 
with a lack of symptoms [76].
Prior studies have used pathogen-specific antibody markers and demonstrated their ability to 
identify waterborne infections that were more widespread than previously appreciated. In the 
massive Cryptosporidium outbreak in Milwaukee in April 1993, a retrospective analysis was 
conducted with banked serum specimens from children that had routine lead level 
surveillance in blood from March to May of that year and showed a seroprevalence increase 
from 15–17 % to 82–87 % for levels of IgG antibody against the immunodominant Triton-17 
and 27 kDa C. parvum antigens [77]. This demonstrated that the outbreak had affected a 
greater proportion of the population with infection when accounting for both symptomatic 
and asymptomatic infections than the previous estimate of 26 % that only surveyed the 
population using the cryptosporidiosis case definition (watery diarrhea) [78]. Teunis et al. 
applied these approaches in the European Union to estimate seroconversion rates for 
Campylobacter infections and found that they were several orders of magnitude higher than 
the notification rates, reflecting both detection deficits in the surveillance and the reality that 
these enteric infections often remain asymptomatic [79]. Frost et al. used serum antibodies 
to Cryptosporidium from a population in Hungary to determine that those using groundwater 
had significantly lower serological responses than those using conventionally filtered and 
disinfected surface water and found that riverbank filtration may be an effective alternative 
treatment to reduce Cryptosporidium exposures and infections for individuals using surface 
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water sources [80]. Tollestrup et al. focused on non-outbreak settings where a low 
probability of outbreak detection should be expected and found a significant association for 
residents in the River Valley of New Mexico using onsite wastewater systems combined with 
private wells to have a strong response to the 27 kDa Cryptosporidium antigen [75]. And 
lastly, in the first postal population-based survey that used saliva, Morris-Cunnington et al. 
used approximately 5500 self-collected oral fluid samples along with a questionnaire of 
demographic and social information to successfully demonstrate that antibody prevalence 
data along with risk factor data can be used to assess the population-based immunity to 
common viral infections in England and Wales [49••].
Such applications of immunological biomarkers in epidemiologic studies also can improve 
knowledge of the temporal patterns of antibody responses, which can be used to extrapolate 
incidence estimates based on cross-sectional data on pathogen-specific antibody responses in 
the population [79, 81, 82]. Others have expanded this approach using parametric statistical 
models [67, 83–85] to determine incidence of infection based on pathogen-specific antibody 
results from a single cross-sectional sampling time. The person-to-person variability in 
antibody responses to a specific pathogen and limited data on temporal patterns of antibody 
responses in various populations affect the precision of such estimates. A pattern of antibody 
responses may also be affected by the number of prior infections and the time interval since 
the previous infection. This may further limit the applicability of the available antibody 
pattern data to populations with comparable epidemiological characteristics or to research 
questions focused on intra-individual variability in antibody responses over time.
In low-income communities where there is less developed drinking water and wastewater 
infrastructure and individuals may experience repeated exposures to multiple waterborne 
pathogens, the application of immunological biomarkers can be used as a monitoring and 
evaluation tool for infrastructure and point-of-use interventions. The multiplex immunoassay 
methodology targeting salivary IgG and IgA responses to potentially waterborne pathogens 
[52••] can be applied as a minimally invasive and objective exposure and outcome screening 
tool to assess the efficacy of interventions designed to reduce pathogen exposure and/or AGI 
illness within a specified population. Such multiplex pathogen antibody measurements could 
improve the evaluation and prioritization of a range of water, sanitation, hygiene, and health 
programs and interventions. Integration of these biomarkers into monitoring activities for the 
Sustainable Development Goals recently adopted at the 2015 UN Summit (https://
sustainabledevelopment.un.org/topics) could improve the evidence base for improved health 
outcomes related to Goal 6, which is to “by 2030, achieve access to adequate and equitable 
sanitation and hygiene for all and end open defecation” (Target 6.2) [86].
Biomarkers of pathogen-specific antibody response can also be used to improve monitoring 
and evaluation of vaccination coverage for specific waterborne infections. Several 
waterborne pathogen vaccines for which antibody response data can be generated include 
Shigella [87], rotavirus [88], cholera [89, 90], and hepatitis A [91] and E [92], among others. 
Such pathogen-specific antibody response biomarkers have particular utility in remote, 
resource-limited population-based settings because they can provide objective measures of 
vaccination coverage when paper-based records and/or recall of vaccination history is 
lacking.
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Challenges and Perspectives for Future Work
Pathogen-specific antibody assays represent a promising tool for understanding the relative 
contribution of waterborne versus other pathways to infectious disease burden in population-
based settings. However, assays based on invasive serum specimens may fail to capture a 
majority of cases in population-based field studies. Because saliva swabs can be self-
administered and returned by mail [49••], salivary antibody assays may increase 
participation in surveys of potentially waterborne infections in populations that are difficult 
to reach, including children, pregnant women, and individuals living in remote, resource-
limited settings. This may facilitate a more fine-scale, spatiotemporal study of the ecology 
and natural history of waterborne disease, including elucidation of optimal points of 
intervention to prevent waterborne pathogen transmission.
While such minimally invasive pathogen-specific salivary antibody biomarkers are 
promising, challenges remain in their broad application to diverse pathogen exposures and 
infections. Not all pathogens elicit a robust systemic or salivary antibody response. 
Additionally, a majority of waterborne infections may be asymptomatic and not result in 
adverse health effects. Therefore, the incidence of infections estimated from cross-sectional 
antibody data may not be representative of disease burden but only reflect recent or 
historical exposure to a pathogen [93]. Nevertheless, cross-sectional antibody response data 
can provide an improved estimate of human exposure to specific pathogens and can be used 
as an epidemiological tool to estimate the contribution of waterborne versus other pathways 
to the total infection pressure. However, the underlying infection and immune response to 
the pathogen must be considered in the interpretation of cross-sectional seroprevalence 
estimates and depend on whether the infection results in lifetime immunity following one 
exposure or the infection is acute and immunity wanes following exposure.
The detection of cytokines in serum and saliva also presents an opportunity to measure the 
onset of waterborne infections. However, cytokines are not capable of identifying a specific 
causative agent; rather, they are more generic biomarkers of infection. The hallmark for a 
viral infection begins with a wave of cytokine production [94], and their presence can be 
employed as a marker of infection (Table 2). Cytokine levels in serum of individuals infected 
with norovirus that were shown to be significantly increased included IFN-gamma, 
interleukin 6 (IL-6), IL-8, IL-12p70, MCP-1, and TNF-alpha 2 days following exposure 
[95]. Evidence has shown that the elevation of cytokines in a newborn's salivary gland 
epithelium promotes secretory immunity [96]. Proinflammatory cytokines can upregulate the 
polymeric Ig receptor (pIgR), including IL-17, which is particularly abundant at mucosal 
sites [97]. The extracellular part of pIgR is essential for resistance against proteolytic 
degradation of the secretory component of IgA (SIgA) found in saliva and the gut mucosa 
[98]. A challenge in using cytokines in saliva is to determine if there is a serum-saliva 
association, for which there is currently limited evidence [99]. The most likely hypothesis is 
that much of the variation in salivary cytokines (e.g., IL-1b, TNF-α, IL-6, IL-8) may be due 
to inflammatory processes in the mouth caused by poor oral health [100] and/or other 
disease processes [101–103]. However, there could be specific hyper-inflammatory 
physiological states (systemic infection/sepsis, burns, etc.) when more of the variance in 
salivary levels of cytokines could be due to systemic circulating cytokine levels [99]. IL-6, 
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which has a major role in the regulation of inflammatory processes, was found to be elevated 
in concentration in both the saliva and serum of inflammatory bowel disease patients when 
compared to reference persons [104]. An area for future study is identifying if a specific 
waterborne pathogen generates a unique or predictive cytokine profile that is observable in 
both saliva and serum.
Conclusion
The ability to estimate waterborne infections via measurements of host immunological 
response at the population level is improving as technological and analytical advancements 
are made. Diagnostic advancements are enabling a paradigm shift in how waterborne 
infections can be measured, not just in clinical settings or outbreak settings but also more 
widely as tools for population-based screening of incidence and prevalence. The 
measurement of salivary antibody responses to specific pathogens as biomarkers of 
waterborne infection holds great potential to expand surveillance to reach larger numbers of 
people in diverse population-based settings. Future work lies in the development of sensitive 
and specific multiplexed serum and salivary immunoassays to measure exposures to, and 
infections with, specific waterborne pathogens.
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The iceberg concept of waterborne infection surveillance. Some of the “host response” 
information listed in Fig. 1 is adapted from Kaslow et al. [105]
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Temporal pattern of antibody responses during infection with a waterborne pathogen
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Table 1
Studies that measured specific waterborne pathogens and estimated which are responsible for the greatest 
population burden of waterborne infection
Region Data source Top waterborne pathogens identified
USA CDC Morbidity Mortality Weekly Report (MMWR) Surveillance for 
waterborne disease outbreaks associated with drinking water, 2011–
2012 [16]
Norovirus and Shiga toxin-producing E. coli
CDC MMWR for Outbreaks of illness associated with recreational 
water, 2011–2012 [24]
Cryptosporidium spp.
Developing countries The Global Enteric Multicenter Study (GEMS)[17] Rotavirus, Cryptosporidium spp., Shigella, 
Giardia spp.,a Campylobacter spp., Vibrio 
choleraeb
The Etiology, Risk Factors, and Interactions of Enteric Infections and 
Malnutrition and the Consequences for Child Health and 
Development Project (MAL-ED) [18]
Giardia spp.c
Ishii et al. (2015) [19] and Hoomagle et al. (2012) [20]
Hepatitis A and E virus
d
a
In univariate analyses, Giardia was identified significantly more frequently in controls than in patients with moderate-to-severe diarrhea aged 12–
59 months in ten of the 14 age-site strata [17]
b
Important in selected sites in GEMS study [17]
c
Giardia spp. were among the top five pathogens in terms of the highest prevalence in diarrheal and non-diarrheal stools for both the 0–11- and the 
12–24-month age groups [18]
d
Hepatitis A and E viruses are the most common causes of feces-transmitted acute viral hepatitis worldwide [19, 20]
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Table 2
Immunological biomarkers of infection for waterborne pathogens that are responsible for the greatest global 
burden of acute gastrointestinal illness (AGI)
Pathogen of interest Specimen Immunologic biomarker response Reference
Cryptosporidium spp. Serum IgG antibody Priest, J. W., et al. [106]; Chappell, C. L., et al. 
[60]; Crump, J. A., et al. [107]; Sarkar, R., et al. 
[108]; Becker, D. J., et al. [109]; Checkley, W., et 
al. [110]
Saliva IgG and IgA antibody Cozon, G., et al. [111]; Moss, D. M., et al. [69]; 
Egorov, A. I., et al. [112]; Griffin, S. M., et al. 
[52••];
Campylobacter Serum IgG, IgM, and IgA antibodies Ang, C. W., et al.; [93]; Teunis, P. F., et al. [81]; 
Rokosz-Chudziak, N. and W. Rastawicki [113].
Stool Cytokines (IL-1β, IL-6, IL-8, TNF-α, and IFN-γ), 
IgA antibodies
Tribble, D. R., et al. [114]; Islam, D., et al. [115];
Saliva IgG and IgA antibodies (responses to acid-glycine 
extracts of C. jejuni strain 81116 and an 
aflagellate mutant, and a whole-cell R2 sonicate)
Cawthraw, S. A., et al. [116]
Giardia intestinalis Serum IgG and IgA antibodies Crump, J. A., et al. [107]; Jiménez, J. C., et al. 
[117]; Priest, J. W., et al. [66]; Moss, D. M., et al. 
[68]
Saliva sIgA, IgA, and IgG antibody (responses against G. 
duodenalis)
Rodriguez, O. L., et al. [118]; El-Gebaly, N. S., et 
al. [119]
Hepatitis A virus Serum IgM and IgG antibodies Vitral, C. L., et al. [11]; Hundekar, S., et al. [120]
Saliva IgM and IgG antibodies Laufer, D. S., et al. [121]; Ochnio, J. J., et al. 
[122]; Morris-Cunnington, M. C., et al. [49••]; 
Tourinho, R. S., et al. [123]
Hepatitis E virus Serum IgG and IgM antibody, cytokines (IL-5, IL-6, 
IL-8, IL-10, IL-2, IFN-γ,TNF-α,TGF-β1, IL-1β
Adjei, A. A., et al. [124]; Pas, S. D., et al. [125]; 
Wu, W. C., et al. [38]; Kumar, A., et al. [126]; Gu, 
G., et al. [127]; Cong, W., et al. [37]; Heaney, C. 
D., et al. [128], Kmush, B. L., et al. [129]
Norovirus Serum IgG and IgA antibodies, cytokines (IL-1, IL-2, 
IL-4, IL-5, IL-6, IL-8, IL-10, and IL-12, IFN-
β,TNF-α)
Erdman, D. D., et al. [64]; Monroe, S. S., et al. 
[39]; Moe, C. L., et al. [40]; Lindesmith, L., et al. 
[58]; Crump, J. A., et al. [107]; Newman, K. L., et 
al. [95]
Stool IgA antibody Iritani, N., et al. [130]; Ramani, S., et al. [131]
Saliva IgA and IgG antibodies Moe, C. L., et al. [40]; Lindesmith, L., et al. [59]; 
Lindesmith, L., et al. [58]; Griffin, S. M., et al. 
[52••]; Griffin, S. M., et al. [53•]
Rotavirus Serum IgM, IgA, and IgG antibodies, cytokines (IFN-γ, 
TNF-α, IL-8, and IL-10)
Grimwood, K., et al. [132]; Azim, T., et al. [133]; 
Xu, J., et al. [134]; Premkumar, P., et al. [135]; 
Sindhu, K. N., et al. [136]; Moon, S. S., et al. 
[137]
Stool IgM, IgA, and IgG antibodies Stals, F., et al. [138]; Grimwood, K., et al. [132]; 
Azim, T., et al. [133]
Saliva IgM, IgA, and IgG antibodies Stals, F., et al. [138]; Grimwood, K., et al. [132]; 
Aiyar, J., et al. [139];
    Friedman, M. G., et al. [140];
Shiga toxin-producing Serum IgG antibodies against 51 O serogroup strains, B 
subunit of Stx2 and Stx1
Ludwig, K., et al. [141]; Kulkarni, H., et al. [142]; 
Fernández-Brando, R. J., et al. [143]; Guirro, M., 
et al. [144]
        Escherichia coli Saliva IgM and IgA antibodies Ludwig, K., et al. [145]; Chart, H., et al. [146]
Shigella Serum IgA, IgM, and IgG subtypes to S. sonnei O-
antigen, IgA and IgG antibodies to S. flexneri 2a 
lipopolysaccharide, total IgA antibody-secreting 
cells (ASC), and anti-LPS IgA ASC, cytokines 
(IFN-γ,TNF-α,TNF-β, IL-4, IL-6, TGF-β)
Van De Verg, L. L., et al. [147]; Raqib, R., et al. 
[148]; Rasolofo-Razanamparany, V., et al. [149]; 
Levine, M. M., et al. [150]; Muhsen, K., et al. 
[151]; Thompson, C. N., et al. [152]
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Pathogen of interest Specimen Immunologic biomarker response Reference
Stool Cytokines (TNF-α, IL-6) Azim, T., et al. [153]
Saliva IgA antibody Schultsz, C., et al. [154];
Vibrio cholerae Serum IgA and IgG antibodies, IgG, IgM, and IgA ASC Chowdhury, F., et al. [155]; Johnson, R. A., et al. 
[156]; Fujii, Y., et al. [157]; Khan, A. I., et al. 
[158]
Stool IgA antibody Qadri, F., et al. [159]
Saliva IgA antibody Jertborn, M., et al. [160]
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